Coherus Oncology to Present CHS-114 Anti-CCR8 Antibody Data Showing Selective Treg Depletion at SITC 2025
Key Insights
Coherus Oncology (search) will present data on CHS-114, an anti-CCR8 (search) cytolytic monoclonal antibody, at the 40th Annual SITC Meeting in November 2025.
The poster presentation will demonstrate CHS-114's ability to achieve selective intratumoral regulatory T cell depletion and favorable immune remodeling in patients with advanced solid tumors (search).
CHS-114 is currently being evaluated in Phase 1b/2a studies across multiple cancer types including head and neck, colorectal, gastric, and esophageal cancers.
Coherus Oncology (search) announced it will present clinical data on its investigational anti-CCR8 (search) antibody CHS-114 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 5-9, 2025, in National Harbor, Maryland. The poster presentation will showcase the drug's selective intratumoral regulatory T cell (Treg) depletion capabilities and favorable immune remodeling effects in patients with advanced solid tumors (search).
Clinical Development Progress
CHS-114 is described as a highly selective cytolytic anti-CCR8 (search) antibody currently undergoing Phase 1b/2a clinical evaluation in patients with advanced solid tumors (search). The ongoing studies include patients with head and neck cancer (search), colorectal cancer (search), gastric cancer (search), and esophageal cancer (search), representing a broad spectrum of difficult-to-treat malignancies.
The poster presentation, designated as Abstract #640, will be held on Saturday, November 8, 2025, at the Prince George ABC Exhibit Halls in the Gaylord National Resort and Convention Center. The presentation title indicates that CHS-114 demonstrates "selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors (search)."
Novel Therapeutic Target
CCR8 (search), or C-C chemokine receptor 8, represents an emerging target in cancer immunotherapy due to its role in regulatory T cell activity and immunosuppression. Regulatory T cells are known to suppress immune responses against tumors, and their selective depletion within the tumor microenvironment could potentially enhance anti-tumor immunity while minimizing systemic immune suppression.
The therapeutic approach targets a specific mechanism of immune evasion used by tumors, potentially offering a new strategy to overcome resistance to current immunotherapies. CHS-114's cytolytic properties suggest it may directly eliminate CCR8 (search)-expressing regulatory T cells rather than simply blocking their function.
Educational Initiative
Beyond the clinical data presentation, Coherus Oncology (search) will participate in SITC's "Targets for Cancer IO: A Deep Dive" webinar series. The sixth webinar, titled "Development of Anti-CCR8 (search) Ab - Mechanisms and Clinical Results," is scheduled for October 22, 2025, from 12:00-2:00 PM Eastern Time.
The webinar will address CCR8 (search)'s role in regulatory T cell activity and immunosuppression, along with the latest advances in developing monoclonal antibodies targeting this chemokine receptor. Faculty members include Dr. Rosh Dias and Dr. Varun Kapoor from Coherus Oncology (search), alongside Dr. Jo Van Ginderachter from Vrije Universiteit Brussel. The session will be moderated by Dr. Enrico Lugli from Humanitas Research Hospital and Dr. Rahul Roychoudhuri from the University of Cambridge.
Company Pipeline Context
CHS-114 represents one component of Coherus Oncology (search)'s broader immuno-oncology pipeline, which focuses on enhancing both innate and adaptive immune responses to enable robust antitumor responses. The company's strategy centers on developing proprietary combinations with its approved PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and advancing new indications across multiple cancer types.
The company's pipeline also includes casdozokitug, a novel IL-27 (search) antagonistic antibody currently in multiple Phase 1/2 and Phase 2 studies for patients with advanced solid tumors (search), including non-small cell lung cancer (search) and hepatocellular carcinoma (search). This diversified approach targets different aspects of the tumor immune microenvironment to potentially overcome various mechanisms of immune evasion.